Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone : vimarsana.com

Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone

SPRING HOUSE, Pa., Feb. 19, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a Phase 2a clinical trial that showed the combination of

Related Keywords

Canada , United States , Japan , Ohio , Spring House , British Columbia , Brucee Sands , Jan Wehkamp , Bridget Kimmel , None Of The Janssen Pharmaceutical Companies , Crohn Colitis Foundation , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , Henryd Janowitz Division Of Gastroenterology , Icahn School Of Medicine At Mount Sinai , Companies Of Johnson , Colitis Organisation , Johnson , European Crohn , Icahn School , Mount Sinai , Mount Sinai Hospital , Vice President , Gastroenterology Disease Area Leader , Janssen Research , Prescribing Information , Medication Guide , Mississippi River Valleys , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Combination Induction Therapy , Moderately To Severely Active Ulcerative Colitis , Results Through Week , Proof Of Concept Study , Combination Therapy With Guselkumab , Participants With Moderately , Severely Active Ulcerative Colitis , Accessed February , Proof Of Concept Clinical Study , Severely Active Ulcerative , Accessed December , National ,